Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Title:
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Cardiovascular medicine and haematology not elsewhere classified; Clinical sciences not elsewhere classified; Public health not elsewhere classified; canagliflozin; Cardiac & Cardiovascular Systems; Cardiovascular System & Cardiology; chronic; clinical trial; DESIGN; diabetes mellitus; EMPAGLIFLOZIN; EVENTS; Life Sciences & Biomedicine; Peripheral Vascular Disease; primary prevention; RATIONALE; renal insufficiency; RISK; Science & Technology; secondary prevention
Description:
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial